CureVac N.V. - חוב לטווח קצר של החברה CVAC

This chart illustrates that the market value of CureVac N.V. (CVAC) stands at 0.01, highlighting a crisis of confidence following the failure of its coronavirus drug. The company is currently rebuilding its image by implementing an improved genetic code for stable vaccine storage. The business relies on its alliance with GSK in the field of influenza vaccinations and is scaling costly research and development for cancer treatments.

For CureVac N.V. (CVAC), which possesses unique stable matrix RNA technology, short-term debt determines current liquidity and financial flexibility. This metric aggregates all obligations with a maturity of up to one year. Analyzing the history of short-term debt allows for an assessment of the company's ability to service loans without emergency equity issuance. A low debt load is critical for maintaining pricing power during the commercialization of vaccines. This confirms the high financial stability of the business.